What are the KDIGO guidelines for initiating and managing ESA therapy and iron supplementation in dialysis patients with anemia?

KDIGO Guidelines for ESA Therapy and Iron Supplementation in Dialysis Patients with Anemia

Initial Evaluation Before Treatment

Before initiating any anemia therapy in dialysis patients, obtain a complete blood count with differential, absolute reticulocyte count, serum ferritin, transferrin saturation (TSAT), and vitamin B12/folate levels to identify all correctable causes of anemia. 1

• Iron deficiency must be addressed first, as it is the most common correctable cause and will impair ESA response if left untreated 2
• Inflammatory states, occult blood loss, and nutritional deficiencies should be identified and corrected before considering ESA therapy 1

Iron Supplementation Thresholds and Targets

Initiate intravenous iron in hemodialysis patients when TSAT is ≤30% and ferritin is ≤500 ng/mL, particularly if you want to increase hemoglobin without starting ESA therapy or reduce ESA dose requirements. 1

Specific Iron Parameters by Patient Population:

• Hemodialysis patients: Maintain TSAT >20% and ferritin >200 ng/mL during ESA therapy 1
• Non-dialysis and peritoneal dialysis patients: Maintain TSAT >20% and ferritin >100 ng/mL during ESA therapy 1

Route of Iron Administration:

• Hemodialysis patients: Use intravenous iron as the preferred route due to superior efficacy and convenience of administration during dialysis sessions 2
• Peritoneal dialysis patients: Subcutaneous or intravenous iron is preferred over oral formulations 1

Upper Safety Limits for Iron:

Stop all intravenous iron immediately when ferritin exceeds 500-800 ng/mL or TSAT exceeds 50%, as further dosing provides no hemoglobin benefit and raises safety concerns. 3, 2

• If ferritin reaches 500-800 ng/mL, withhold iron and monitor every 3 months 3
• Resume iron only after ferritin falls below 800 ng/mL and TSAT drops below 50%, using one-third to one-half of the previous weekly dose 3
• If ferritin exceeds 1000 ng/mL, complete discontinuation is mandatory regardless of hemoglobin level 3

ESA Therapy Initiation

Do not initiate ESA therapy until hemoglobin falls below 10.0 g/dL (100 g/L), and only after correcting iron deficiency and other reversible causes of anemia. 1, 2

Hemoglobin Targets:

Target a hemoglobin level of 10.0-11.5 g/dL (100-115 g/L) in adult dialysis patients, avoiding levels above 11.5 g/dL due to increased cardiovascular risk and mortality. 1

• The rate of hemoglobin rise should be 1.0-2.0 g/dL per month, not exceeding 1.0 g/dL in any 2-week period 1
• Never intentionally increase hemoglobin above 13.0 g/dL (130 g/L), as this is associated with increased mortality and cardiovascular events 1

ESA Dosing and Administration:

• Initial dose: Determine based on hemoglobin level, body weight, and clinical circumstances; typical starting dose is 50-100 units/kg three times weekly for epoetin 1
• Route for hemodialysis patients: Either intravenous or subcutaneous administration is acceptable, though subcutaneous requires 20-30% less dose 1
• Route for peritoneal dialysis patients: Subcutaneous administration is preferred 1

Dose Adjustments:

Adjust ESA dose based on hemoglobin concentration, rate of hemoglobin change, current ESA dose, and clinical circumstances; decrease dose rather than withholding when downward adjustment is needed. 1

• Make dose adjustments no more frequently than every 2-4 weeks 1
• If hemoglobin rises above 12.0 g/dL, reduce ESA dose by 25-50% 1
• If hemoglobin exceeds 13.0 g/dL, withhold ESA until hemoglobin falls to 12.0 g/dL, then restart at 25-50% lower dose 1

Monitoring Frequency

Monitor hemoglobin twice weekly for the first 2-6 weeks after initiating or adjusting ESA therapy, then at least monthly once stable in hemodialysis patients. 1

• For non-dialysis patients on ESA therapy, measure hemoglobin at least every 3 months during maintenance phase 1
• Monitor ferritin and TSAT at least every 3 months in all patients receiving ESA therapy 4, 2
• During ESA initiation or dose escalation, check iron parameters monthly 4

Timing of Laboratory Measurements:

• Draw predialysis hemoglobin levels before the midweek dialysis session to avoid variability from ultrafiltration and the longer interdialytic interval 1
• Wait at least 4-8 weeks after IV iron administration before rechecking ferritin, as it becomes falsely elevated immediately after dosing 3

ESA Hyporesponsiveness

Classify patients as having initial ESA hyporesponsiveness if hemoglobin does not increase after the first month of appropriate weight-based ESA dosing. 1

Management Algorithm:

1. Do not escalate ESA dose beyond double the initial weight-based dose 1

2. Evaluate and treat specific causes of poor ESA response:

   • Recheck iron parameters (target TSAT >20%, ferritin >200 ng/mL for HD patients) 1
   • Assess for infection, inflammation (check C-reactive protein) 1
   • Evaluate for occult blood loss 1
   • Consider hyperparathyroidism, aluminum toxicity, hemoglobinopathies 1
   • Rule out pure red cell aplasia if on ESA >8 weeks with sudden hemoglobin drop of 0.5-1.0 g/dL per week 1

3. If ferritin is >800 ng/mL and TSAT <25%, consider a trial of IV iron only if hemoglobin remains below target and ESA dose is high (≥300 IU/kg/week epoetin or ≥1.5 mcg/kg/week darbepoetin), carefully weighing risks versus benefits 1

Acquired ESA Hyporesponsiveness:

Classify as acquired hyporesponsiveness when a patient previously stable on ESA requires two dose increases of up to 50% beyond their stable dose to maintain hemoglobin. 1

• Avoid escalating beyond double the previously stable dose 1
• Investigate for new causes of ESA resistance using the same algorithm as initial hyporesponsiveness 1

Adjuvant Therapies

Do not use androgens, vitamin C, vitamin D, vitamin E, folic acid, L-carnitine, or pentoxifylline as adjuvants to ESA treatment, as they lack proven benefit. 1

Blood Transfusion Strategy

Avoid blood transfusions when possible by maintaining hemoglobin above 9.0 g/dL through appropriate ESA and iron therapy, as transfusions carry risks of alloimmunization, infection, and iron overload. 1

• Balance the risks of transfusion against the risks of anemia and ESA therapy when hemoglobin falls below 9.0 g/dL 1

Critical Pitfalls to Avoid

• Never start ESA therapy without first optimizing iron stores (TSAT >20%, ferritin >100-200 ng/mL depending on dialysis status) 1, 2
• Never check ferritin within 4 weeks of IV iron administration, as falsely elevated readings may lead to inappropriate continuation of therapy 3
• Never continue IV iron when ferritin exceeds 800-1000 ng/mL, even if hemoglobin remains suboptimal, as the patient is unlikely to respond and safety data are lacking 3
• Never target hemoglobin above 11.5 g/dL due to increased cardiovascular mortality demonstrated in multiple randomized trials 1
• Never escalate ESA dose indefinitely in hyporesponsive patients; stop at double the initial or stable dose and investigate alternative causes 1
• Do not use postdialysis hemoglobin values for monitoring, as they are artificially elevated by ultrafiltration 1